Grundlæggende statistik
| CIK | 1011060 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to EKIMAS Corporation
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-11737 NORDICUS PARTNERS CORPO |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Fo |
|
| August 11, 2025 |
Exhibit 99.1 |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 August 11, 2025 (August 7, 2025) Date of report (date of earliest event reported) Nordicus Partners Corporation (Exact Name of Registrant as Specified in Charter) Delaware Commission File No. |
|
| August 11, 2025 |
Exhibit 99.2 |
|
| August 7, 2025 |
Nordicus Partners Corporation Appoints Three New Members to Its Board of Directors Exhibit 99.1 Nordicus Partners Corporation Appoints Three New Members to Its Board of Directors Beverly Hills, California, August 7, 2025…Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a business accelerator and holding company specializing in providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves on the U.S. market, announced |
|
| August 7, 2025 |
Nordicus Partners Corporation Director Agreement Exhibit 10.3 Nordicus Partners Corporation Director Agreement This Director Agreement (this “Agreement”) is entered into as of August 7, 2025, by and between Nordicus Partners Corporation, a Delaware corporation (the “Company”), and Andrew Ritter (the “Director”). 1. Position. The Company hereby appoints Director to serve as a member of the Board of Directors of the Company (the “Board”) for the t |
|
| August 7, 2025 |
Nordicus Partners Corporation Director Agreement Exhibit 10.2 Nordicus Partners Corporation Director Agreement This Director Agreement (this “Agreement”) is entered into as of August 7, 2025, by and between Nordicus Partners Corporation, a Delaware corporation (the “Company”), and Kim T. Mücke (the “Director”). 1. Position. The Company hereby appoints Director to serve as a member of the Board of Directors of the Company (the “Board”) for the t |
|
| August 7, 2025 |
Nordicus Partners Corporation Director Agreement Exhibit 10.1 Nordicus Partners Corporation Director Agreement This Director Agreement (this “Agreement”) is entered into as of August 7, 2025, by and between Nordicus Partners Corporation, a Delaware corporation (the “Company”), Torben Jensen (the “Director”). 1. Position. The Company hereby appoints Director to serve as a member of the Board of Directors of the Company (the “Board”) for the term |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 August 7, 2025 (August 7, 2025) Date of report (date of earliest event reported) Nordicus Partners Corporation (Exact Name of Registrant as Specified in Charter) Delaware Commission File No. |
|
| August 5, 2025 |
Prospectus Supplement No. 2 (to Prospectus dated December 23, 2024) Prospectus Supplement No. 2 Filed pursuant to Rule 424(b)(3) Registration No. 333-283709 Nordicus Partners Corporation Prospectus Supplement No. 2 (To Final Prospectus dated December 23, 2024) This Prospectus Supplement No. 2 supplements and amends the final prospectus dated December 23, 2024, as previously supplemented (the “Fina |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-11737 NORDICUS PARTNERS CORPORATION |
|
| July 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 July 3, 2025 (June 16, 2025) Date of report (date of earliest event reported) Nordicus Partners Corporation (Exact Name of Registrant as Specified in Charter) Delaware Commission File No. |
|
| July 1, 2025 |
Exhibit 10.2 THIRD AMENDED AND RESTATED EXECUTIVE CONSULTING AGREEMENT This THIRD AMENDED AND RESTATED EXECUTIVE CONSULTING AGREEMENT (this “Agreement”) is made and entered into as of the 1st day of July, 2025 (the “Effective Date”), by and between Nordicus Partners Corporation, a Delaware corporation (the “Company”), and Bennett J. Yankowitz (“Executive”), and is made with reference to the follow |
|
| July 1, 2025 |
Exhibit 10.1 THIRD AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This THIRD AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of the 1st day of July, 2025 (the “Effective Date”), by and between Nordicus Partners Corporation, a Delaware corporation (the “Company”), and Henrik Rouf (“Executive”), and is made with reference to the following facts |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 July 1, 2025 (June 30, 2025) Date of report (date of earliest event reported) NORDICUS PARTNERS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware Commission File No. |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on F |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 June 11, 2025 (June 11, 2025) Date of report (date of earliest event reported) Nordicus Partners Corporation (Exact Name of Registrant as Specified in Charter) Delaware Commission File No. |
|
| June 4, 2025 |
Prospectus Supplement No. 1 (to Prospectus dated November 1, 2021) Prospectus Supplement No. 1 Filed pursuant to Rule 424(b)(3) Registration No. 333-283709 Nordicus Partners Corporation Prospectus Supplement No. 1 (To Final Prospectus dated December 23, 2024) This Prospectus Supplement No. 1 supplements and amends the final prospectus dated December 23, 2024, as previously supplemented (the “Final |
|
| April 2, 2025 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-11737 NORDICUS PARTNERS CORPORATIO |
|
| April 1, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 April 1, 2025 (April 1, 2025) Date of report (date of earliest event reported) Nordicus Partners Corporation (Exact Name of Registrant as Specified in Charter) Delaware Commission File No. |
|
| April 1, 2025 |
Exhibit 99.1 |
|
| March 6, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 March 6, 2025 (March 6, 2025) Date of report (date of earliest event reported) Nordicus Partners Corporation (Exact Name of Registrant as Specified in Charter) Delaware Commission File No. |
|
| March 6, 2025 |
Exhibit 99.1 |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report o |
|
| January 2, 2025 |
Warrant dated as of December 30, 2024 issued by Nordicus Partners Corporation to GK Partners ApS. Exhibit 10.1 NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITI |
|
| January 2, 2025 |
Exhibit 99.1 |
|
| January 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 January 2, 2025 (December 30, 2024) Date of report (date of earliest event reported) Nordicus Partners Corporation (Exact Name of Registrant as Specified in Charter) Delaware Commission File No. |
|
| January 2, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 January 2, 2025 (December 30, 2024) Date of report (date of earliest event reported) Nordicus Partners Corporation (Exact Name of Registrant as Specified in Charter) Delaware Commission File No. |
|
| December 26, 2024 |
Nordicus Partners Corporation 280 South Beverly Dr. Suite 505 Beverly Hills, CA 90212 Nordicus Partners Corporation 280 South Beverly Dr. Suite 505 Beverly Hills, CA 90212 December 26, 2024 Via EDGAR Correspondence U.S. Securities and Exchange Commission Division of Corporation Finance Office of Trade & Services 100 F Street, N.E. Washington, DC 20549 Attention: Alyssa Wall Re: Nordicus Partners Corporation Registration Statement on Form S-1 Filed December 10, 2024 File No. 333-283 |
|
| December 23, 2024 |
As filed with the Securities and Exchange Commission on December 23, 2024 As filed with the Securities and Exchange Commission on December 23, 2024 Registration Statement No. |
|
| December 17, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Nordicus Partners Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(4) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock reserved for issuance pursuant to awards under the Registrant’s 2024 Incentive Stock Plan (the “2024 Plan”) 457 (h) 7,000,000 (2)(3) $ 3. |
|
| December 17, 2024 |
As filed with the Securities and Exchange Commission on December 17, 2024 As filed with the Securities and Exchange Commission on December 17, 2024 Registration No. |
|
| December 10, 2024 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Title of each Class of Securities to be Registered Shares to be Registered(1) Proposed Maximum Aggregate Offering Price Per Share(1) Maximum Aggregate Offering Price(2) Amount of Registration Fee Shares of common stock, par value $0. |
|
| December 10, 2024 |
Employment Agreement dated April 17, 2023, with Henrik Rouf Exhibit 10.12 |
|
| December 10, 2024 |
SC 13D 1 formsc13d.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Nordicus Partners Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 28265K205 (CUSIP Number) AC Nordic ApS Dyrehavevej 3B DK-2930 Klampenborg Denmark (+45) 31 38 08 34 (Name, Address and Telephone Number of Person Authorized to |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to SCHEDULE 13D Under the Securities Exchange Act of 1934 Nordicus Partners Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 28265K205 (CUSIP Number) Alteral Therapeutics ApS Dyrehavevej 3B DK-2930 Klampenborg Denmark (+45) 53 84 27 43 (Name, Address and Telephone Number of Person Author |
|
| December 10, 2024 |
Exhibit 3.2 CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF NORDICUS PARTNERS CORPORATION The undersigned, Henrik Rouf, hereby certifies that: 1. He is the duly elected and acting President and Chief Executive Officer of Nordicus Partners Corporation, a Delaware corporation. 2. The Certificate of Incorporation of this corporation was originally filed with the Secretary of State of Dela |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 5 to SCHEDULE 13D Under the Securities Exchange Act of 1934 Nordicus Partners Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 28265K205 (CUSIP Number) GK Partners ApS Dyrehavevej 3B DK-2930 Klampenborg, Denmark (+45) 20 30 59 61 (Name, Address and Telephone Number of Person Authorized to |
|
| December 10, 2024 |
Exhibit 10.14 |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Nordicus Partners Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 28265K205 (CUSIP Number) ABCHill Holding ApS Mesterlodden 3A, 1. DK-2820 Gentofte Denmark (+45) 21 42 24 12 (Name, Address and Telephone Number of Person Authorized to Receive Notice |
|
| December 10, 2024 |
As filed with the Securities and Exchange Commission on December 10, 2024 As filed with the Securities and Exchange Commission on December 10, 2024 Registration Statement No. |
|
| December 10, 2024 |
Consulting Agreement dated ____ with Bennett J. Yankowitz Exhibit 10.13 |
|
| December 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 December 3, 2024 (November 27, 2024) Date of report (date of earliest event reported) Nordicus Partners Corporation (Exact Name of Registrant as Specified in Charter) Delaware Commission File No. |
|
| December 3, 2024 |
Consulting Agreement, dated November 27, 2024, between the Company and Harbor Access LLC Exhibit 10.1 |
|
| December 3, 2024 |
Consulting Agreement, dated November 27, 2024, between the Company and ESG Advisor Group, L.L.C. Exhibit 10.2 |
|
| November 14, 2024 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-11737 NORDICUS PARTNERS CORPORATI |
|
| November 13, 2024 |
Nordicus Partners Corporation Acquires the Remaining 5% Shares In Orocidin A/S Exhibit 99.1 Nordicus Partners Corporation Acquires the Remaining 5% Shares In Orocidin A/S Beverly Hills, California. November 12, 2024…Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves on the U.S. market, today announced it has |
|
| November 13, 2024 |
Exhibit 10.1 STOCK PURCHASE AND SALE AGREEMENT THIS STOCK PURCHASE AND SALE AGREEMENT (this “Agreement”) is made and entered into as of November 11, 2024, among the persons identified on Exhibit A to this Agreement (each, a “Seller” and collectively the “Sellers”), and Nordicus Partners Corporation, a Delaware corporation (“Buyer”), and is made with reference to the following facts: A. Sellers col |
|
| November 13, 2024 |
SC 13D/A 1 form13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to SCHEDULE 13D Under the Securities Exchange Act of 1934 Nordicus Partners Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 28265K205 (CUSIP Number) Alteral Therapeutics ApS Dyrehavevej 3B DK-2930 Klampenborg Denmark (+45) 53 84 27 43 (Name, Address and Telephone |
|
| November 13, 2024 |
Exhibit 10.1 STOCK PURCHASE AND SALE AGREEMENT THIS STOCK PURCHASE AND SALE AGREEMENT (this “Agreement”) is made and entered into as of November 11, 2024, among the persons identified on Exhibit A to this Agreement (each, a “Seller” and collectively the “Sellers”), and Nordicus Partners Corporation, a Delaware corporation (“Buyer”), and is made with reference to the following facts: A. Sellers col |
|
| November 13, 2024 |
Nordicus Partners Corporation Acquires Bio-Convert ApS Exhibit 99.1 Nordicus Partners Corporation Acquires Bio-Convert ApS Beverly Hills, California. November 11, 2024…Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves on the U.S. market, today announced that it entered into an agreeme |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 November 13, 2024 (November 11, 2024) Date of report (date of earliest event reported) Nordicus Partners Corporation (Exact Name of Registrant as Specified in Charter) Delaware Commission File No. |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to SCHEDULE 13D Under the Securities Exchange Act of 1934 Nordicus Partners Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 28265K205 (CUSIP Number) JE Pitzner Holding ApS Pilevej 4, DK-4180 Sorø Denmark (+45) 40 70 11 24 (Name, Address and Telephone Number of Person Authorized to Recei |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 November 13, 2024 (November 11, 2024) Date of report (date of earliest event reported) Nordicus Partners Corporation (Exact Name of Registrant as Specified in Charter) Delaware Commission File No. |
|
| November 5, 2024 |
SC 13D/A 1 formsc13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to SCHEDULE 13D Under the Securities Exchange Act of 1934 Nordicus Partners Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 28265K205 (CUSIP Number) Alteral Therapeutics ApS Dyrehavevej 3B DK-2930 Klampenborg Denmark (+45) 53 84 27 43 (Name, Address and Telepho |
|
| November 5, 2024 |
SC 13D/A 1 formsc13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to SCHEDULE 13D Under the Securities Exchange Act of 1934 Nordicus Partners Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 28265K205 (CUSIP Number) JE Pitzner Holding ApS Pilevej 4, DK-4180 Sorø Denmark (+45) 40 70 11 24 (Name, Address and Telephone Number of |
|
| October 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement NORDICUS PARTNERS CORPORATION |
|
| October 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement NORDICUS PARTNERS CORPORATION (Name of Registran |
|
| August 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 4 to SCHEDULE 13D Under the Securities Exchange Act of 1934 Nordicus Partners Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 28265K205 (CUSIP Number) GK Partners ApS Dyrehavevej 3B DK-2930 Klampenborg, Denmark (+45) 20 30 59 61 (Name, Address and Telephone Number of Person Authorized to |
|
| August 19, 2024 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-11737 NORDICUS PARTNERS CORPORATION (N |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Fo |
|
| July 3, 2024 |
Exhibit 10.10 SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of the 1st day of April, 2024 (the “Effective Date”), by and between Nordicus Partners Corporation, a Delaware corporation (the “Company”), and Henrik Rouf (“Executive”), and is made with reference to the following f |
|
| July 3, 2024 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-11737 NORDICUS PARTNERS CORPORATION (Name of |
|
| July 3, 2024 |
Exhibit 10.11 SECOND AMENDED AND RESTATED EXECUTIVE CONSULTING AGREEMENT This SECOND AMENDED AND RESTATED EXECUTIVE CONSULTING AGREEMENT (this “Agreement”) is made and entered into as of the 1st day of April, 2024 (the “Effective Date”), by and between Nordicus Partners Corporation, a Delaware corporation (the “Company”), and Bennett J. Yankowitz (“Executive”), and is made with reference to the fo |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on F |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Nordicus Partners Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 28265K205 (CUSIP Number) Alteral Therapeutics ApS Mesterlodden 3 A, First Floor DK-2820 Gentofte Denmark (+45) 53 84 27 43 (Name, Address and Telephone Number of Person Authorized to |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Nordicus Partners Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 28265K205 (CUSIP Number) JE Pitzner Holding ApS Pilevej 4, DK-4180 Sorø Denmark (+45) 40 70 11 24 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Comm |
|
| June 4, 2024 |
Nordicus Partners Corporation Appoints Peter Severin as Chairman Of The Board of Directors Exhibit 99.1 Nordicus Partners Corporation Appoints Peter Severin as Chairman Of The Board of Directors Beverly Hills, California, June 4, 2024…Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves on the U.S. market, announced today |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 June 4, 2024 (June 3, 2024) Date of report (date of earliest event reported) Nordicus Partners Corporation (Exact Name of Registrant as Specified in Charter) Delaware Commission File No. |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to SCHEDULE 13D Under the Securities Exchange Act of 1934 Nordicus Partners Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 28265K205 (CUSIP Number) GK Partners ApS Dyrehavevej 3B DK-2930 Klampenborg, Denmark (+45) 20 30 59 61 (Name, Address and Telephone Number of Person Authorized to |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement NORDICUS PARTNERS CORPORATION (Name of Registran |
|
| May 16, 2024 |
Exhibit 10.1 |
|
| May 16, 2024 |
Nordicus Partners Corporation Acquires 95% Stake in Orocidin A/S Exhibit 99.1 Nordicus Partners Corporation Acquires 95% Stake in Orocidin A/S Beverly Hills, California. May 15, 2024…Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. Life Sciences companies with optimal conditions to establish themselves on the U.S. market, announced today that it has entered into a |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 May 16, 2024 (May 13, 2024) Date of report (date of earliest event reported) Nordicus Partners Corporation (Exact Name of Registrant as Specified in Charter) Delaware Commission File No. |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 4 to SCHEDULE 13D Under the Securities Exchange Act of 1934 Nordicus Partners Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 28265K205 (CUSIP Number) Henrik Rouf Islands Brygge 75B, P1 DK-2300 Copenhagen S, Denmark (+45) 2112 2111 (Name, Address and Telephone Number of Person Authorized |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to SCHEDULE 13D Under the Securities Exchange Act of 1934 Nordicus Partners Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 28265K205 (CUSIP Number) GK Partners ApS Dyrehavevej 3B DK-2930 Klampenborg, Denmark (+45) 20 30 59 61 (Name, Address and Telephone Number of Person Authorized to |
|
| February 6, 2024 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-11737 NORDICUS PARTNERS CORPORATIO |
|
| December 11, 2023 |
Nordicus Partners Corporation 3651 Lindell Road Suite D565 Las Vegas, NV 89103 Nordicus Partners Corporation 3651 Lindell Road Suite D565 Las Vegas, NV 89103 December 11, 2023 Via EDGAR Correspondence U. |
|
| December 6, 2023 |
As filed with the Securities and Exchange Commission on December 6, 2023 As filed with the Securities and Exchange Commission on December 6, 2023 Registration Statement No. |
|
| December 6, 2023 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Title of each Class of Securities to be Registered Shares to be Registered(1) Proposed Maximum Aggregate Offering Price Per Share(1) Maximum Aggregate Offering Price(2) Amount of Registration Fee Shares of common stock, par value $0. |
|
| December 6, 2023 |
Amended and Restated Certificate of Incorporation Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NORDICUS PARTNERS CORPORATION The undersigned, Henrik Rouf, hereby certifies that: 1. He is the duly elected and acting President and Chief Executive Officer of Nordicus Partners Corporation, a Delaware corporation. 2. The Certificate of Incorporation of this corporation was originally filed with the Secretary of State of Delaware un |
|
| December 6, 2023 |
Exhibit 10.8 AMENDED AND RESTATED EXECUTIVE CONSULTING AGREEMENT This AMENDED AND RESTATED EXECUTIVE CONSULTING AGREEMENT (this “Agreement”) is made and entered into as of the 5th day of September, 2023 (the “Effective Date”), by and between Nordicus Partners Corporation, a Delaware corporation (the “Company”), and Bennett J. Yankowitz (“Executive”), and is made with reference to the following fac |
|
| December 6, 2023 |
Exhibit 10.11 |
|
| December 6, 2023 |
Exhibit 3.2 BYLAWS OF NORDICUS PARTNERS CORPORATION (A DELAWARE CORPORATION) ARTICLE I - CORPORATE OFFICES 1.1 REGISTERED OFFICE. The registered office of the Corporation shall be fixed in the Corporation’s certificate of incorporation, as the same may be amended from time to time. 1.2 OTHER OFFICES. The Corporation’s Board of Directors (the “Board”) may at any time establish branch or other offic |
|
| December 6, 2023 |
Exhibit 10.7 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of the 5th day of September, 2023 (the “Effective Date”), by and between Nordicus Partners Corporation, a Delaware corporation (the “Company”), and Henrik Rouf (“Executive”), and is made with reference to the following facts: A. Th |
|
| November 27, 2023 |
BYLAWS OF NORDICUS PARTNERS CORPORATION (A DELAWARE CORPORATION) ARTICLE I - CORPORATE OFFICES Exhibit 3.2 BYLAWS OF NORDICUS PARTNERS CORPORATION (A DELAWARE CORPORATION) ARTICLE I - CORPORATE OFFICES 1.1 REGISTERED OFFICE. The registered office of the Corporation shall be fixed in the Corporation’s certificate of incorporation, as the same may be amended from time to time. 1.2 OTHER OFFICES. The Corporation’s Board of Directors (the “Board”) may at any time establish branch or other offic |
|
| November 27, 2023 |
Exhibit 10.7 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of the 5th day of September, 2023 (the “Effective Date”), by and between Nordicus Partners Corporation, a Delaware corporation (the “Company”), and Henrik Rouf (“Executive”), and is made with reference to the following facts: A. Th |
|
| November 27, 2023 |
NORDICUS PARTNERS CORPORATION 3651 Lindell Road Suite D565 Las Vegas, NV 8910352 NORDICUS PARTNERS CORPORATION 3651 Lindell Road Suite D565 Las Vegas, NV 8910352 November 27, 2023 Via Edgar Correspondence Jennie Beysolow, Esq. |
|
| November 27, 2023 |
Exhibit 10.11 |
|
| November 27, 2023 |
Amended and Restated Certificate of Incorporation Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NORDICUS PARTNERS CORPORATION The undersigned, Henrik Rouf, hereby certifies that: 1. He is the duly elected and acting President and Chief Executive Officer of Nordicus Partners Corporation, a Delaware corporation. 2. The Certificate of Incorporation of this corporation was originally filed with the Secretary of State of Delaware un |
|
| November 27, 2023 |
Exhibit 10.8 AMENDED AND RESTATED EXECUTIVE CONSULTING AGREEMENT This AMENDED AND RESTATED EXECUTIVE CONSULTING AGREEMENT (this “Agreement”) is made and entered into as of the 5th day of September, 2023 (the “Effective Date”), by and between Nordicus Partners Corporation, a Delaware corporation (the “Company”), and Bennett J. Yankowitz (“Executive”), and is made with reference to the following fac |
|
| November 27, 2023 |
As filed with the Securities and Exchange Commission on November 27, 2023 As filed with the Securities and Exchange Commission on November 27, 2023 Registration Statement No. |
|
| November 27, 2023 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Title of each Class of Securities to be Registered Shares to be Registered(1) Proposed Maximum Aggregate Offering Price Per Share(1) Maximum Aggregate Offering Price(2) Amount of Registration Fee Shares of common stock, par value $0. |
|
| November 13, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-11737 NORDICUS PARTNERS CORPORATI |
|
| November 13, 2023 |
As filed with the Securities and Exchange Commission on November 13, 2023 As filed with the Securities and Exchange Commission on November 13, 2023 Registration Statement No. |
|
| November 13, 2023 |
Exhibit 10.11 |
|
| November 13, 2023 |
Exhibit 10.8 AMENDED AND RESTATED EXECUTIVE CONSULTING AGREEMENT This AMENDED AND RESTATED EXECUTIVE CONSULTING AGREEMENT (this “Agreement”) is made and entered into as of the 5th day of September, 2023 (the “Effective Date”), by and between Nordicus Partners Corporation, a Delaware corporation (the “Company”), and Bennett J. Yankowitz (“Executive”), and is made with reference to the following fac |
|
| November 13, 2023 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Title of each Class of Securities to be Registered Shares to be Registered(1) Proposed Maximum Aggregate Offering Price Per Share(1) Maximum Aggregate Offering Price(2) Amount of Registration Fee Shares of common stock, par value $0. |
|
| November 13, 2023 |
Amended and Restated Certificate of Incorporation Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NORDICUS PARTNERS CORPORATION The undersigned, Henrik Rouf, hereby certifies that: 1. He is the duly elected and acting President and Chief Executive Officer of Nordicus Partners Corporation, a Delaware corporation. 2. The Certificate of Incorporation of this corporation was originally filed with the Secretary of State of Delaware un |
|
| November 13, 2023 |
BYLAWS OF NORDICUS PARTNERS CORPORATION (A DELAWARE CORPORATION) ARTICLE I - CORPORATE OFFICES Exhibit 3.2 BYLAWS OF NORDICUS PARTNERS CORPORATION (A DELAWARE CORPORATION) ARTICLE I - CORPORATE OFFICES 1.1 REGISTERED OFFICE. The registered office of the Corporation shall be fixed in the Corporation’s certificate of incorporation, as the same may be amended from time to time. 1.2 OTHER OFFICES. The Corporation’s Board of Directors (the “Board”) may at any time establish branch or other offic |
|
| November 13, 2023 |
Exhibit 10.7 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of the 5th day of September, 2023 (the “Effective Date”), by and between Nordicus Partners Corporation, a Delaware corporation (the “Company”), and Henrik Rouf (“Executive”), and is made with reference to the following facts: A. Th |
|
| November 13, 2023 |
NORDICUS PARTNERS CORPORATION 3651 Lindell Road Suite D565 Las Vegas, NV 8910352 NORDICUS PARTNERS CORPORATION 3651 Lindell Road Suite D565 Las Vegas, NV 8910352 November 13, 2023 Via Edgar Correspondence Jennie Beysolow, Esq. |
|
| October 24, 2023 |
Amended and Restated Certificate of Incorporation Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NORDICUS PARTNERS CORPORATION The undersigned, Henrik Rouf, hereby certifies that: 1. He is the duly elected and acting President and Chief Executive Officer of Nordicus Partners Corporation, a Delaware corporation. 2. The Certificate of Incorporation of this corporation was originally filed with the Secretary of State of Delaware un |
|
| October 24, 2023 |
Exhibit 10.8 AMENDED AND RESTATED EXECUTIVE CONSULTING AGREEMENT This AMENDED AND RESTATED EXECUTIVE CONSULTING AGREEMENT (this “Agreement”) is made and entered into as of the 5th day of September, 2023 (the “Effective Date”), by and between Nordicus Partners Corporation, a Delaware corporation (the “Company”), and Bennett J. Yankowitz (“Executive”), and is made with reference to the following fac |
|
| October 24, 2023 |
BYLAWS OF NORDICUS PARTNERS CORPORATION (A DELAWARE CORPORATION) ARTICLE I - CORPORATE OFFICES Exhibit 3.2 BYLAWS OF NORDICUS PARTNERS CORPORATION (A DELAWARE CORPORATION) ARTICLE I - CORPORATE OFFICES 1.1 REGISTERED OFFICE. The registered office of the Corporation shall be fixed in the Corporation’s certificate of incorporation, as the same may be amended from time to time. 1.2 OTHER OFFICES. The Corporation’s Board of Directors (the “Board”) may at any time establish branch or other offic |
|
| October 24, 2023 |
As filed with the Securities and Exchange Commission on October 24, 2023 As filed with the Securities and Exchange Commission on October 24, 2023 Registration Statement No. |
|
| October 24, 2023 |
Exhibit 10.7 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of the 5th day of September, 2023 (the “Effective Date”), by and between Nordicus Partners Corporation, a Delaware corporation (the “Company”), and Henrik Rouf (“Executive”), and is made with reference to the following facts: A. Th |
|
| October 24, 2023 |
Exhibit 10.11 |
|
| October 24, 2023 |
NORDICUS PARTNERS CORPORATION 3651 Lindell Road Suite D565 Las Vegas, NV 8910352 NORDICUS PARTNERS CORPORATION 3651 Lindell Road Suite D565 Las Vegas, NV 8910352 October 24, 2023 Via Edgar Correspondence Jennie Beysolow, Esq. |
|
| October 24, 2023 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Title of each Class of Securities to be Registered Shares to be Registered(1) Proposed Maximum Aggregate Offering Price Per Share(1) Maximum Aggregate Offering Price(2) Amount of Registration Fee Shares of common stock, par value $0. |
|
| September 19, 2023 |
As filed with the Securities and Exchange Commission on September 19, 2023 As filed with the Securities and Exchange Commission on September 19, 2023 Registration Statement No. |
|
| September 19, 2023 |
Exhibit 10.8 AMENDED AND RESTATED EXECUTIVE CONSULTING AGREEMENT This AMENDED AND RESTATED EXECUTIVE CONSULTING AGREEMENT (this “Agreement”) is made and entered into as of the 5th day of September, 2023 (the “Effective Date”), by and between Nordicus Partners Corporation, a Delaware corporation (the “Company”), and Bennett J. Yankowitz (“Executive”), and is made with reference to the following fac |
|
| September 19, 2023 |
Amended and Restated Certificate of Incorporation Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NORDICUS PARTNERS CORPORATION The undersigned, Henrik Rouf, hereby certifies that: 1. He is the duly elected and acting President and Chief Executive Officer of Nordicus Partners Corporation, a Delaware corporation. 2. The Certificate of Incorporation of this corporation was originally filed with the Secretary of State of Delaware un |
|
| September 19, 2023 |
BYLAWS OF NORDICUS PARTNERS CORPORATION (A DELAWARE CORPORATION) ARTICLE I - CORPORATE OFFICES Exhibit 3.2 BYLAWS OF NORDICUS PARTNERS CORPORATION (A DELAWARE CORPORATION) ARTICLE I - CORPORATE OFFICES 1.1 REGISTERED OFFICE. The registered office of the Corporation shall be fixed in the Corporation’s certificate of incorporation, as the same may be amended from time to time. 1.2 OTHER OFFICES. The Corporation’s Board of Directors (the “Board”) may at any time establish branch or other offic |
|
| September 19, 2023 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Title of each Class of Securities to be Registered Shares to be Registered(1) Proposed Maximum Aggregate Offering Price Per Share(1) Maximum Aggregate Offering Price(2) Amount of Registration Fee Shares of common stock, par value $0. |
|
| September 19, 2023 |
Exhibit 10.7 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of the 5th day of September, 2023 (the “Effective Date”), by and between Nordicus Partners Corporation, a Delaware corporation (the “Company”), and Henrik Rouf (“Executive”), and is made with reference to the following facts: A. Th |
|
| September 18, 2023 |
ASNB / EKIMAS Corporation / Gk Partners ApS Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to SCHEDULE 13D Under the Securities Exchange Act of 1934 Nordicus Partners Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 28265K205 (CUSIP Number) GK Partners ApS Dyrehavevej 3B DK-2930 Klampenborg, Denmark (+45) 20 30 59 61 (Name, Address and Telephone Number of Person Authorized to |
|
| August 31, 2023 |
ASNB / EKIMAS Corporation / Rouf Henrik Activist Investment SC 13D/A 1 formsc13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to SCHEDULE 13D Under the Securities Exchange Act of 1934 Nordicus Partners Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 28265K205 (CUSIP Number) Henrik Rouf Islands Brygge 75B, P1 DK-2300 Copenhagen S, Denmark (+45) 2112 2111 (Name, Address and Telephone Nu |
|
| August 18, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 NORDICUS PARTNERS CORPORATION (Nam |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Fo |
|
| July 20, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-11737 NORDICUS PARTNERS C |
|
| July 20, 2023 |
Certificate of Incorporation and Amendments Exhibit 3.1 |
|
| July 14, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 NORDICUS PARTNERS CORPORATION (Name of sm |
|
| July 14, 2023 |
Certificate of Incorporation and Amendments Exhibit 3.1 |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on F |
|
| June 20, 2023 |
Exhibit 10.1 STOCK PURCHASE AND SALE AGREEMENT THIS STOCK PURCHASE AND SALE AGREEMENT (this “Agreement”) is made and entered into as of June 20, 2023, among GK Partners ApS, a Danish private limited company (Anpartsselskab) (“Seller”), and Nordicus Partners Corporation, a Delaware corporation (“Buyer”), and is made with reference to the following facts: A. Seller is the owner of 5,000,000 shares o |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 June 20, 2023 (June 20, 2023) Date of report (date of earliest event reported) Nordicus Partners Corporation (Exact Name of Registrant as Specified in Charter) Delaware Commission File No. |
|
| June 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 June 9, 2023 (June 9, 2023) Date of report (date of earliest event reported) Nordicus Partners Corporation (Exact Name of Registrant as Specified in Charter) Delaware Commission File No. |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 May 23, 2023 (May 13, 2023) Date of report (date of earliest event reported) Nordicus Partners Corporation (Exact Name of Registrant as Specified in Charter) Delaware Commission File No. |
|
| May 23, 2023 |
Exhibit 16.1 |
|
| May 22, 2023 |
EKIMAS CORPORATION CHANGES NAME TO NORDICUS PARTNERS CORPORATION AND TICKER SYMBOL TO ‘NORD’ Exhibit 99.1 EKIMAS CORPORATION CHANGES NAME TO NORDICUS PARTNERS CORPORATION AND TICKER SYMBOL TO ‘NORD’ Las Vegas, Nevada. May 22, 2023…EKIMAS Corporation (OTC PINK: NORD) (“EKIMAS” or the “Company”), a financial consulting company specializing in providing Nordic companies with the best possible conditions to establish themselves on the U.S. market, today announced that its common stock began t |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 May 22, 2023 (May 13, 2023) Date of report (date of earliest event reported) Nordicus Partners Corporation (Exact Name of Registrant as Specified in Charter) Delaware Commission File No. |
|
| May 22, 2023 |
Exhibit 3.1 |
|
| May 3, 2023 |
Consulting Agreement, dated as of April 1, 2023, between EKIMAS Corporation and Bennett J. Yankowitz Exhibit 10.2 EXECUTIVE CONSULTING AGREEMENT This EXECUTIVE CONSULTING AGREEMENT (this “Agreement”) is made and entered into as of the 1st day of April, 2023 (the “Effective Date”), by and between EKIMAS Corporation, a Delaware corporation (the “Company”), and Bennett J. Yankowitz (“Executive”), and is made with reference to the following facts: A. The Company desires to retain Executive on. Consul |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 April 17, 2023 (April 17, 2023) Date of report (date of earliest event reported) EKIMAS Corporation (Exact Name of Registrant as Specified in Charter) Delaware Commission File No. |
|
| May 3, 2023 |
Employment Agreement, dated as of April 1, 2023, between EKIMAS Corporation and Henrik Rouf Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of the 1st day of April, 2023 (the “Effective Date”), by and between EKIMAS Corporation, a Delaware corporation (the “Company”), and Henrik Rouf (“Executive”), and is made with reference to the following facts: A. The Company desires to employ Executive as its Chief Execut |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 March 1, 2023 (February 23, 2023) Date of report (date of earliest event reported) EKIMAS Corporation (Exact Name of Registrant as Specified in Charter) Delaware Commission File No. |
|
| March 1, 2023 |
EX-99.1 4 ex99-1.htm Exhibit 99.1 NORDICUS PARTNERS A/S FINANCIAL STATEMENTS JUNE 30, 2022 AND DECEMBER 31, 2021 Index to Financial Statement Statements Report of Independent Registered Public Accounting Firm 3 Balance Sheets as of June 30, 2022 and December 31, 2021 4 Statements of Operations for the periods from August 12, 2020, through December 31, 2021 and January 1, 2022 through June 30, 2022 |
|
| March 1, 2023 |
Exhibit 14.1 |
|
| March 1, 2023 |
NORDICUS PARTNERS A/S COMPLETES REVERSE ACQUISITION TRANSACTION WITH EKIMAS CORPORTION EX-99.3 6 ex99-3.htm Exhibit 99.3 NORDICUS PARTNERS A/S COMPLETES REVERSE ACQUISITION TRANSACTION WITH EKIMAS CORPORTION Las Vegas, Nevada. March 1, 2023…Nordicus Partners A/S (“Nordicus”), a financial consulting company, specializing in providing Nordic companies with the best possible conditions to establish themselves on the U.S. market, today announced the completion of a reverse acquisition w |
|
| March 1, 2023 |
Exhibit 2.1 CONTRIBUTION AGREEMENT This Contribution Agreement (this “Agreement”) is made and entered into as of February 23, 2023 by and among (i) EKIMAS Corporation, a Delaware corporation (the “Purchaser”), (ii) Nordicus Partners A/S, a Danish stock corporation (Aktieselskab) (the “Company”), and GK Partners ApS, Henrik Rouf and LIFE SCIENCE POWER HOUSE ApS (the “Sellers”). The Purchaser, the C |
|
| March 1, 2023 |
EKIMAS CORPORATION UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION EX-99.2 5 ex99-2.htm Exhibit 99.2 EKIMAS CORPORATION UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial information is based on the financial statements of EKIMAS Corporation (the “Company”) and Nordicus Partners A/S, a Danish stock corporation (“Nordicus”), after entering into an agreement on February 23, 2023, to whereby th |
|
| February 14, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 EKIMAS CORPORATION (Name of sm |
|
| November 30, 2022 |
Warrant to Purchase Common Stock, dated November 28, 2022, issued to David Volpe Exhibit 10.1 NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITI |
|
| November 30, 2022 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 November 29, 2022 Date of report (date of earliest event reported) EKIMAS Corporation (Exact Name of Registrant as Specified in Charter) Delaware Commission File No. |
|
| November 30, 2022 |
Warrant to Purchase Common Stock, dated November 28, 2022, issued to Bennett J. Yankowitz EX-10.2 3 ex10-2.htm Exhibit 10.2 NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITI |
|
| November 14, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 EKIMAS CORPORATION (Name of s |
|
| October 17, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 October 14, 2022 Date of report (date of earliest event reported) EKIMAS Corporation (Exact Name of Registrant as Specified in Charter) Delaware Commission File No. |
|
| October 17, 2022 |
Demand Promissory Note, dated October 14, 2022, made by the Company to the Lender. Exhibit 10.1 DEMAND PROMISSORY NOTE $40,000.00 October 14, 2022 (?Execution Date?) For value received, EKIMAS Corporation, a Delaware corporation (the ?Company?), with principal offices at 3651 Lindell Road ? Suite D565, Las Vegas, NV 89103, hereby promises to pay GK Partners ApS (the ?Holder?), or its assigns, the original principal sum of up to Forty Thousand Dollars ($40,000.00) (the ?Principal |
|
| October 11, 2022 |
EX-16.1 2 ex16-1.htm Exhibit 16.1 Liggett & Webb, P.A. 1901 S. Congress Ave, Suite 101 Boynton Beach, FL 33426 October 11, 2022 U.S. Securities & Exchange Commission Office of the Chief Accountant 100 F Street, NE Washington, DC 20549 Ladies and Gentlemen We have read the statements included under Item 4.01 in the Form 8-K, dated October 7, 2022 of EKIMAS Corporation to be filed with the Securitie |
|
| October 11, 2022 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 October 7, 2022 Date of report (date of earliest event reported) EKIMAS Corporation (Exact Name of Registrant as Specified in Charter) Delaware Commission File No. |
|
| September 8, 2022 |
ASNB / AdvanSource Biomaterials Corp. / Oerbekker Henrik Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 EKIMAS Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 28265K205 (CUSIP Number) Henrik Oerbekker 308 High Street Croydon, Surry CRO 1NG United Kingdom (+352) 661 366 003 (Name, Address and Telephone Number of Person Authorized to Receive Notices an |
|
| August 26, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 EKIMAS CORPORATION (Name of small |
|
| August 15, 2022 |
NT 10-Q 1 formnt10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q |
|
| July 21, 2022 |
ASNB / AdvanSource Biomaterials Corp. / Gk Partners ApS Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 EKIMAS Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 28265K205 (CUSIP Number) GK Partners ApS Mesterlodden 3 b DK-2820 Gentofte, Denmark (+45) 60 84 83 20 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communicati |
|
| July 8, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 EKIMAS Corporation (N |
|
| June 28, 2022 |
ASNB / AdvanSource Biomaterials Corp. / Rouf Henrik Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to SCHEDULE 13D Under the Securities Exchange Act of 1934 EKIMAS Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 28265K205 (CUSIP Number) Henrik Rouf Islands Brygge 75B, P1 DK-2300 Copenhagen S, Denmark (+45) 2112 2111 (Name, Address and Telephone Number of Person Authorized to Receive |
|
| June 28, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 EKIMAS Corporation (Name of small busines |
|
| April 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 April 11, 2022 Date of report (date of earliest event reported) EKIMAS Corporation (Exact Name of Registrant as Specified in Charter) Delaware Commission File No. |
|
| April 12, 2022 |
Warrant dated as of April 1, 2022 issued by EKIMAS Corporation to GK Partners AsP. Exhibit 10.1 NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITI |
|
| March 21, 2022 |
ASNB / AdvanSource Biomaterials Corp. / Rouf Henrik Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 EKIMAS Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 28265K205 (CUSIP Number) Henrik Rouf Islands Brygge 75B, P1 DK-2300 Copenhagen S, Denmark (+45) 2112 2111 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communi |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 March 17, 2022 Date of report (date of earliest event reported) EKIMAS Corporation (Exact Name of Registrant as Specified in Charter) Delaware Commission File No. |
|
| January 14, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 EKIMAS CORPORATION (Name of sm |
|
| December 29, 2021 |
DEF 14C 1 formdef14c.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement EKIMAS CORPORATION (Nam |
|
| November 12, 2021 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 EKIMAS CORPORATION (Name of s |
|
| November 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement EKIMAS CORPORATION (Name of Registrant as Specif |
|
| October 18, 2021 |
Exhibit 10.1 STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (this ?Agreement?) is made and entered into as of October 12, 2021 by and between (i) Reddington Partners LLC, a California limited liability company (the ?Purchaser?), and (ii) EKIMAS Corporation, a Delaware corporation (the ?Company?). The Purchaser and the Company are sometimes referred to herein individually as a ?Party? and, |
|
| October 18, 2021 |
EX-10.2 3 ex10-2.htm Exhibit 10.2 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of October 12, 2021, is made by and between EKIMAS Corporation, a Delaware corporation (the “Company”), and Bennett J. Yankowitz (“Indemnitee”). A. The Company desires to attract and retain the services of highly qualified individuals as directors, officers, employees and Agents. B. The Compa |
|
| October 18, 2021 |
ASNB / AdvanSource Biomaterials Corp. / Rouf Henrik Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 EKIMAS Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 00767T 109 (CUSIP Number) Henrik Rouf Islands Brygge 75B, P1 DK-2300 Copenhagen S, Denmark (+45) 2112 2111 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Commun |
|
| October 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 October 12, 2021 Date of report (date of earliest event reported) EKIMAS Corporation (Exact Name of Registrant as Specified in Charter) Delaware Commission File No. |
|
| September 23, 2021 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 EKIMAS CORPORATION (Name of small |
|
| September 22, 2021 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 EKIMAS Corporation (Name of small busines |
|
| September 22, 2021 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) 10-K/A 1 form10-ka.htm U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2021 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-2803 |
|
| September 13, 2021 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 EKIMAS CORPORATION (Name of sm |
|
| September 10, 2021 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 form10-q.htm U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 EKIMAS CO |
|
| September 10, 2021 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 EKIMAS CORPORATION (Name of small |
|
| August 27, 2021 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 27, 2021 (August 24, 2021) EKIMAS Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-28034 04-3186647 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| August 27, 2021 |
EXHIBIT 16.1 August 27, 2021 Securities and Exchange Commission 100 F Street, N.W. Washington, DC 20549-7561 Dear Sirs/Madams: We have read Item 4.01 of EKIMAS Corporation (the ?Company?) Form 8-K dated August 24, 2021, and are in agreement with the statements relating only to RBSM LLP contained therein. We have no basis to agree or disagree with other statements of the Company contained therein. |
|
| July 20, 2021 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2020 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 EKIMAS Corporatio |
|
| July 16, 2021 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2020 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 EKIMAS Corporation (Name of small bus |
|
| June 29, 2021 |
NT 10-K 1 formnt10-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 20-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: March 31, 2021 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transiti |
|
| October 13, 2020 |
8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 13, 2020 (October 9, 2020) EKIMAS CORPORATION (Exact name of Registrant as Specified in its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) |
|
| June 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 29, 2020 (June 29, 2020) EKIMAS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-11737 04-3186647 (State or Other Jurisdiction of Incorporation) (Commi |
|
| April 6, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 6, 2020 (April 6, 2020) EKIMAS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-11737 04-3186647 (State or Other Jurisdiction of Incorporation) (Commi |
|
| April 6, 2020 |
EKIMAS Corporation Announces Special Cash Distribution Press Release Announcing Asset Sale - Final (00741749-7).DOCX Exhibit 99.1 EKIMAS Corporation Announces Special Cash Distribution April 6, 2020 – Canton, MA – EKIMAS Corporation (OTCQB: “ASNB”), formerly AdvanSource Biomaterials Corporation (the “Company”), which sold substantially all of its assets to Mitsubishi Chemical Performance Polymers, Inc. on January 31, 2020, today announced that the Com |
|
| April 3, 2020 |
Certificate of Amendment to Certificate of Incorporation Exhibit 3.1 For Form 8-K - Certificate of Amendment (00783745-2).DOCX CERTIFICATE OF AMENDMENT OF THE CERTIFICATE OF INCORPORATION OF ADVANSOURCE BIOMATERIALS CORPORATION AdvanSource Biomaterials Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1.The name of the Corporation is AdvanSource Biomaterials Corporation. The Co |
|
| April 3, 2020 |
8-K 1 asnb2004038k.htm EKIMAS FORM 8K (200403) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 3, 2020 (March 3, 2020) EKIMAS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-11737 04-3186647 (State |
|
| April 1, 2020 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 ADVANSOURCE BIOMATERIALS C |
|
| February 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 20-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: December 31, 2019 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q |
|
| February 6, 2020 |
EX-99.1 2 f8k013120ex99-1advansource.htm PRESS RELEASE DATED FEBRUARY 3, 2020 Exhibit 99.1 AdvanSource Biomaterials Corporation Announces Completion of the Sale of Substantially All of its Assets to a Subsidiary of Mitsubishi Chemical America WILMINGTON, Mass, Feb. 03, 2020 (GLOBE NEWSWIRE) - AdvanSource Biomaterials Corporation (OTC: ASNB) (“AdvanSource” or the “Company”), a materials technology |
|
| February 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 31, 2020 AdvanSource Biomaterials Corporation (Exact Name of Registrant as Specified in Charter) Delaware 001-11737 04-3186647 (State or Other Jurisdiction of Incorporation) ( |
|
| January 24, 2020 |
Submission of Matters to a Vote of Security Holders 8-K 1 f8k012120advansource.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 21, 2020 AdvanSource Biomaterials Corporation (Exact Name of Registrant as Specified in Charter) Delaware 001-11737 04-3186647 (S |
|
| December 30, 2019 |
ASNB / AdvanSource Biomaterials Corp. DEFM14A - - DEFM14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant S Filed by a Party other than the Registrant £ Check the appropriate box: £ Preliminary Proxy Statement £ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) S Defin |
|
| December 18, 2019 |
Form of Voting and Support Agreement Exhibit 10.2 VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is made and entered into as of November 25, 2019 by and between Mitsubishi Chemical Performance Polymers, Inc., a Delaware corporation (“Buyer”) and the undersigned stockholder (the “Stockholder”) of AdvanSource Biomaterials Corporation, a Delaware corporation (“Seller”). Capitalized terms that are used |
|
| December 18, 2019 |
ASNB / AdvanSource Biomaterials Corp. / ADAMS MICHAEL F - SCHEDULE 13D Activist Investment SC 13D 1 sc13d1219adamsadvansource.htm SCHEDULE 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* AdvanSource Biomaterials Corporation (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 00767T 109 (CUSIP Number) c/o Michael F. Adams 229 Andover Street, Wilmington, Massachusetts 01887 (9 |
|
| December 18, 2019 |
EX-10.1 2 sc13d1219ex10-1advan.htm ASSET PURCHASE AGREEMENT, DATED NOVEMBER 25, 2019, BY AND BETWEEN ADVANSOURCE BIOMATERIALS CORPORATION AND MITSUBISHI CHEMICAL PERFORMANCE POLYMERS, INC. Exhibit 10.1 Execution Version Redactions with respect to certain portions hereof are denoted with “***” ASSET PURCHASE AGREEMENT BY AND BETWEEN MITSUBISHI CHEMICAL PERFORMANCE POLYMERS, INC. AND ADVANSOURCE BIO |
|
| December 17, 2019 |
ASNB / AdvanSource Biomaterials Corp. PREM14A - - PRELIMINARY PROXY STATEMENT PREM14A 1 pre14a1219advansourcebio.htm PRELIMINARY PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Us |
|
| December 2, 2019 |
Exhibit 2.1 Execution Version Redactions with respect to certain portions hereof are denoted with “***” ASSET PURCHASE AGREEMENT BY AND BETWEEN MITSUBISHI CHEMICAL PERFORMANCE POLYMERS, INC. AND ADVANSOURCE BIOMATERIALS CORPORATION Dated as of November 25, 2019 TABLE OF CONTENTS Page ARTICLE I Definitions 1 ARTICLE II Purchase and Sale 11 Section 2.01 Purchase and Sale of Assets 11 Section 2.02 Ex |
|
| December 2, 2019 |
Form of Voting and Support Agreement EX-10.1 3 f8k1219ex10-1advansource.htm VOTING AND SUPPORT AGREEMENT Exhibit 10.1 VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is made and entered into as of November 25, 2019 by and between Mitsubishi Chemical Performance Polymers, Inc., a Delaware corporation (“Buyer”) and the undersigned stockholder (the “Stockholder”) of AdvanSource Biomaterials Corporation, |
|
| December 2, 2019 |
Form of Voting and Support Agreement Exhibit 10.1 VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is made and entered into as of November 25, 2019 by and between Mitsubishi Chemical Performance Polymers, Inc., a Delaware corporation (“Buyer”) and the undersigned stockholder (the “Stockholder”) of AdvanSource Biomaterials Corporation, a Delaware corporation (“Seller”). Capitalized terms that are used |
|
| December 2, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 25, 2019 AdvanSource Biomaterials Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-28034 04-3186647 (State or Other Jurisdiction of Incorporation) |
|
| December 2, 2019 |
Exhibit 2.1 Execution Version Redactions with respect to certain portions hereof are denoted with “***” ASSET PURCHASE AGREEMENT BY AND BETWEEN MITSUBISHI CHEMICAL PERFORMANCE POLYMERS, INC. AND ADVANSOURCE BIOMATERIALS CORPORATION Dated as of November 25, 2019 TABLE OF CONTENTS Page ARTICLE I Definitions 1 ARTICLE II Purchase and Sale 11 Section 2.01 Purchase and Sale of Assets 11 Section 2.02 Ex |
|
| December 2, 2019 |
ASNB / AdvanSource Biomaterials Corp. DEFA14A - - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 25, 2019 AdvanSource Biomaterials Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-28034 04-3186647 (State or Other Jurisdiction of Incorporation) |
|
| November 26, 2019 |
Press Release issued November 25, 2019. Exhibit 99.1 AdvanSource Biomaterials Corporation Enters into a Definitive Agreement to Sell Substantially All of its Assets to a Subsidiary of Mitsubishi Chemical America November 25, 2019—Wilmington, Mass.— AdvanSource Biomaterials Corporation (OTC: ASNB) (“AdvanSource” or the “Company”), a materials technology company specializing in medical grade polymers for long and short term applications, |
|
| November 26, 2019 |
ASNB / AdvanSource Biomaterials Corp. DEFA14A - - CURRENT REPORT DEFA14A 1 f8k112519advansourcebio.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 25, 2019 AdvanSource Biomaterials Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-28034 04-31 |
|
| November 26, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 25, 2019 AdvanSource Biomaterials Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-28034 04-3186647 (State or Other Jurisdiction of Incorporation) |
|
| November 26, 2019 |
Exhibit 99.1 AdvanSource Biomaterials Corporation Enters into a Definitive Agreement to Sell Substantially All of its Assets to a Subsidiary of Mitsubishi Chemical America November 25, 2019—Wilmington, Mass.— AdvanSource Biomaterials Corporation (OTC: ASNB) (“AdvanSource” or the “Company”), a materials technology company specializing in medical grade polymers for long and short term applications, |
|
| November 13, 2019 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 ADVANSOURCE BIOMATERIALS CORP |
|
| September 30, 2019 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 ADVANSOURCE BIOMATERIALS CORPORATI |
|
| August 23, 2019 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2019 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-28034 AdvanSource Biomate |
|
| August 22, 2019 |
ASNB / AdvanSource Biomaterials Corp. 10-K - Annual Report - 190331 ASNB FORM 10-K U U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2019 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 AdvanSource Biomaterials Corporation (N |
|
| August 14, 2019 |
ASNB / AdvanSource Biomaterials Corp. NT 10-Q - - 190814 ASNB FORM 12B-25 FOR 190630 FORM 10-Q Form 12b-25 for March 31, 2009 Form 10-Q (M0077514.DOC;2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 20-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: June 30, 2019 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition |
|
| July 1, 2019 |
ASNB / AdvanSource Biomaterials Corp. NT 10-K - - 190701 ASNB FORM 12B-25 FOR 190331 FORM 10-K Form 12b-25 for March 31, 2009 Form 10-Q (M0077514.DOC;2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 20-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: March 31, 2019 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition |
|
| February 19, 2019 |
ASNB / AdvanSource Biomaterials Corp. 181231 ASNB FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2018 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-28034 AdvanSou |
|
| February 14, 2019 |
ASNB / AdvanSource Biomaterials Corp. FORM 12B-25 FOR MARCH 31, 2009 FORM 10-Q (M0077514.DOC;2) Form 12b-25 for March 31, 2009 Form 10-Q (M0077514.DOC;2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 20-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: December 31, 2018 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transit |
|
| November 14, 2018 |
ASNB / AdvanSource Biomaterials Corp. 180930 ASNB FORM 10-Q (Quarterly Report) U UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-28034 Advan |
|
| August 14, 2018 |
ASNB / AdvanSource Biomaterials Corp. 180630 ASNB FORM 10-Q (Quarterly Report) U UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-28034 AdvanSourc |
|
| July 30, 2018 |
ASNB / AdvanSource Biomaterials Corp. 180331 ASNB FORM 10-KA #1 (Annual Report) U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2018 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 AdvanSource Biomateri |
|
| July 16, 2018 |
ASNB / AdvanSource Biomaterials Corp. 180331 ASNB FORM 10-K (Annual Report) U U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2018 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 AdvanSource Biomaterials Corporation (N |
|
| June 29, 2018 |
ASNB / AdvanSource Biomaterials Corp. 180629 ASNB FORM 12B-25 FOR 180331 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 20-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: March 31, 2018 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ |
|
| February 14, 2018 |
ASNB / AdvanSource Biomaterials Corp. ASNB 171231 FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2017 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-28034 AdvanSou |
|
| November 14, 2017 |
ASNB / AdvanSource Biomaterials Corp. 170930 ASNB FORM 10-Q (Quarterly Report) U UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-28034 Advan |
|
| August 22, 2017 |
Final Revised 8-K 07 31 2017 (00525963).DOCX UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported):August 22, 2017 (August 16, 2017) ADVANSOURCE BIOMATERIALS CORPORATION (Exact name of Registrant as Specified in its Charter) DELAWARE (Sta |
|
| August 22, 2017 |
2017 Non-Qualified Equity Incentive Plan ** Exhibit 10.37 ADVANSOURCE BIOMATERIALS CORPORATION 2017 NON-QUALIFIED EQUITY INCENTIVE PLAN 1. Purpose. The purpose of this 2017 Non-qualified Equity Incentive Plan (this ?Plan?) of AdvanSource Biomaterials Corporation, , a Delaware corporation (the ?Company?), is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons wh |
|
| August 14, 2017 |
ASNB / AdvanSource Biomaterials Corp. 170630 ASNB FORM 10-Q (Quarterly Report) U UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-28034 AdvanSourc |
|
| July 25, 2017 |
ASNB / AdvanSource Biomaterials Corp. 170331 ASNB FORM 10-K/A#1 (Annual Report) 10-K/A 1 asnb170331ka10kz.htm 170331 ASNB FORM 10-K/A#1 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2017 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period f |
|
| June 26, 2017 |
ASNB / AdvanSource Biomaterials Corp. 170331 ASNB FORM 10-K (Annual Report) U U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2017 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 AdvanSource Biomaterials Corporation (N |
|
| February 9, 2017 |
AdvanSource Biomaterials 161231 ASNB FORM 10-Q (Quarterly Report) U UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2016 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-28034 AdvanS |
|
| November 16, 2016 |
AdvanSource Biomaterials 160930 ASNB FORM 10-Q/A #1 (Quarterly Report) U UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A (Amendment No. 1) (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 14, 2016 |
AdvanSource Biomaterials 161114 ASNB FORM 10-Q (Quarterly Report) U UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-28034 AdvanSour |
|
| August 12, 2016 |
AdvanSource Biomaterials 160630 ASNB FORM 10Q (Quarterly Report) U UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-28034 AdvanSourc |
|
| July 29, 2016 |
AdvanSource Biomaterials 160729 ASNB FORM 10-KA (Annual Report) U U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2016 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 AdvanSource Biomate |
|
| June 27, 2016 |
AdvanSource Biomaterials 160331 ASNB FORM 10-K (Annual Report) U U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2016 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 AdvanSource Biomaterials Corporation (N |
|
| February 12, 2016 |
ASNB / AdvanSource Biomaterials Corp. 10-Q - Quarterly Report - 151231 ASNB FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2015 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-28034 AdvanSou |
|
| February 3, 2016 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 3, 2016 (February 2, 2016) AdvanSource Biomaterials Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-28034 04-3186647 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| February 3, 2016 |
Converted by EDGARwiz Exhibit 16.1 February 3, 2016 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated February 3, 2016 of AdvanSource Biomaterials Corporation and are in agreement with the statements contained in the first sentence with regards to the dismissal of Liggett & Webb, P.A. of the first paragraph, |
|
| November 16, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-28034 AdvanSo |
|
| August 14, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-28034 AdvanSource |
|
| July 28, 2015 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2015 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 AdvanSource Biomateri |
|
| July 14, 2015 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2015 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 AdvanSource Biomaterials Corporation (Nam |
|
| June 29, 2015 |
AdvanSource Biomaterials 150629 FORM 12B-25_150331 FORM 10K Form 12b-25 for March 31, 2009 Form 10-Q (M0077514.DOC;2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 20-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: March 31, 2014 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition |
|
| February 17, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2014 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-28034 AdvanSou |
|
| December 11, 2014 |
EXHIBIT 99.1 December 8. 2014 Mr. William O’Neill Chairman of the Board of Directors Advansource Biomaterials Corporation 229 Andover Street Wilmington, MA 01887 Dear Mr. O’Neill, After almost 2 years as the full-time Chief Financial Officer of Advansource Biomaterials Corporation, I have decided, for my own personal reasons, that I can be of greater service to the Company in a consulting role as |
|
| December 11, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 11, 2014 (December 8, 2014) AdvanSource Biomaterials Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-28034 04-3186647 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| November 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-28034 AdvanSo |
|
| August 13, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-28034 AdvanSource |
|
| July 29, 2014 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2014 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 AdvanSource Biomateri |
|
| July 14, 2014 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2014 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-28034 AdvanSource Biomaterials Corporation (Nam |
|
| June 30, 2014 |
ASNB / AdvanSource Biomaterials Corp. NT 10-K - - 140630 ASNB FORM 12B-25 FOR 140331 FORM 10K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 20-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: March 31, 2014 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ |
